Poland pharmaceutical market size
 
Poland has one of the largest pharmaceutical markets in Europe. It is the 5th largest pharmaceutical market in the EU, and the largest pharmaceutical market in central Europe. Poland's pharmaceutical market was valued at 10 billion USD in 2021, and has been growing at a rate of 5.2% CAGR between the years 2013 to 2019. However, due to the COVID-19 pandemic, the accelerated growth previously noted dropped to a 2% CAGR in 2020. The pharmaceutical industry in Poland generates about 1.7% of the country's total GDP.
Poland's pharmaceutical manufacturing focal point is generic medicine. With a predicted 7% CAGR in production of generic medicine, compared with 5.9% CAGR in OTC production, and 2.7% CAGR in innovative medicine production (2017-2025). The Polish health care system relays mostly on generic medicine, as a means to reduce costs. However, in recent years there has been a shift towards implementing more biologic medicines in the national reimbursement scheme. Hospital spending on high-priced biological medicines has increased rapidly from 6.8% in 2018, to 17.1% this year.

Pharma14 tracks the Polish market closely in terms of medicine pricing, consumption, shortages, EU parallel trade as well as constant market competitive analytical tools.

Sample Data:
Insulin Glargine pricing, consumption levels for 2021 and current shortage issues in Polish market.